GSK Secures Another Legal Victory in Latest Zantac Verdict

Legal Victory:
GSK has won the latest trial over claims that the discontinued heartburn drug Zantac caused cancer, with a jury finding the drug was not liable for the plaintiff's colorectal cancer.

Ongoing Litigation:
Despite this victory, GSK faces tens of thousands of Zantac-related lawsuits, with over 75,000 cases allowed to proceed in Delaware.

Scientific Consensus:
GSK maintains that there is no consistent or reliable evidence linking ranitidine to an increased risk of cancer, citing 16 epidemiological studies.

Settlements and Dismissals:
GSK has settled several cases confidentially and had some voluntarily dismissed by plaintiffs, including a recent case in Illinois where the plaintiff alleged Zantac caused breast cancer.

FDA Action:
The FDA ordered the removal of all ranitidine products from the market in 2020 due to concerns over the presence of the possible carcinogen N-nitrosodimethylamine (NDMA).

Appeal Plans:
GSK plans to appeal the Delaware ruling that allows plaintiff expert testimony, joined by other drugmakers like Pfizer, Sanofi, and Boehringer Ingelheim.